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OBJECTIVES We sought to evaluate the safety and efficacy of percutaneous transmyocardial revasculariza-
tion (PTMR) in patients with refractory angina caused by one or more chronic total
occlusions (CTOs) of a native coronary artery.
BACKGROUND Previous unblinded, randomized trials of PTMR in patients with end-stage coronary artery
disease and refractory angina have demonstrated significant relief of angina and increased
exercise duration. Whether such benefits would be realized in blinded patients with less
extensive coronary artery disease is unknown.
METHODS A total of 141 consecutive patients with class III or IV angina caused by one or more
chronically occluded native coronary arteries in which a percutaneous coronary intervention
(PCI) had failed were prospectively randomized, at 17 medical centers, in the same procedure,
to PTMR plus maximal medical therapy (MMT) (n  71) or MMT only (n  70). Blinding
was achieved through heavy sedation, dark goggles and the concurrent performance of PCI
in all patients.
RESULTS Baseline characteristics were similar between the two groups. A median number of 20 laser
channels were created in patients randomized to PTMR. At six months, the anginal class
improved by two or more classes in 49% of patients assigned to PTMR and in 37% of those
assigned to MMT (p  0.33). The median increase in exercise duration from baseline to six
months was 64 s with PTMR versus 52 s with MMT (p  0.73). There were no differences
in the six-month rates of death (8.6% vs. 8.8%), myocardial infarction (4.3% vs. 2.9%) or any
revascularization (4.3% vs. 5.9%) in the PTMR and MMT groups, respectively (p  NS for
all).
CONCLUSIONS In patients with class III or IV angina caused by nonrecanalizable CTOs, the performance of
PTMR does not result in a greater reduction in angina, improvement in exercise duration or
survival free of adverse cardiac events, as compared with MMT only. (J Am Coll Cardiol
2002;39:1581–7) © 2002 by the American College of Cardiology Foundation
The inability to successfully pass a guidewire into the true
distal lumen of a chronically occluded coronary artery is the
most frequent cause of failed percutaneous coronary inter-
vention (PCI) and one of the most common indications for
coronary artery bypass graft surgery (CABG) (1–6). Fur-
thermore, many more patients with occluded vessels not
amenable to PCI are treated conservatively with anti-
anginal medication. The likelihood of successful recanaliza-
tion of chronic total occlusions (CTOs) has reached a
plateau at 50% to 70% over the last decade, despite steady
improvements in angioplasty equipment, operator technique
and the introduction of new devices (1–6).
Percutaneous transmyocardial revascularization (PTMR)
is a technique whereby holmium/yttrium aluminum garnet
(YAG) laser energy is transmitted to the endocardial surface
through fiberoptic cables to photo-acoustically create
partial-thickness myocardial channels (7–9). In two separate
randomized trials, PTMR, as compared with maximal
medical therapy (MMT), was found to reduce angina and
improve exercise capacity in patients with advanced isch-
emic heart disease and class III or IV angina (10,11). The
results of these studies, however, have been questioned
because of a lack of blinding, raising the possibility that the
benefits observed with PTMR may have been due to the
placebo effect (12,13). Moreover, a third trial in which a
different laser system was used (but which was blinded),
found no incremental improvement in symptoms or func-
tional capacity with PTMR (14).
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Therefore, we performed a prospective, multicenter,
single-blinded, randomized trial of PTMR versus MMT in
patients with a nonrecanalizable CTO and class III or IV
angina in whom continued medical therapy was planned.
METHODS
Patient group. Consecutive patients meeting each of the
following inclusion criteria were considered for enrollment:
1) Canadian Heart Association class III or IV angina,
despite maximally tolerated anti-anginal medications; 2)
planned PCI of CTO in a native coronary artery; 3) no
other lesions present requiring PCI or CABG; 4) myocar-
dial viability in the distribution subtended by the CTO, as
verified either by thallium scintigraphic imaging, echocar-
diography, radionuclide ventriculography or left ventricu-
lography; 5) myocardial wall thickness 9 mm in the area
intended for treatment by PTMR (i.e., the nonrevascular-
izable region and surrounding margin), as measured by
two-dimensional echocardiography; and 6) continued med-
ical management if PCI was unsuccessful.
Patients were excluded if any of the following conditions
were present: 1) left ventricular ejection fraction 30%; 2)
myocardial infarction (MI) within three months, left ven-
tricular aneurysm or mural thrombus; 3) aortic stenosis,
aortic regurgitation or a prosthetic aortic valve; 4) decom-
pensated heart failure; 5) ventricular tachycardia or fibrilla-
tion within one week; 6) the inability to perform a baseline
modified Bruce exercise stress test for any reason other than
severe angina, or if the electrocardiogram was uninterpret-
able for ischemia (e.g., left bundle branch block, left
ventricular hypertrophy or Wolf-Parkinson-White syn-
drome); 8) a previous PCI was performed within the last six
months; 9) a noncardiac condition with anticipated life
expectancy 1 year; 10) participation in other investiga-
tional drug or device studies; or 11) the inability or unwill-
ingness to comply with the follow-up procedures or provide
informed consent.
The protocol was approved by the Human Investigational
Review Board at each site, and all patients provided written,
informed consent.
Study protocol and procedure. A modified Bruce exercise
test and transthoracic echocardiography for the assessment
of left ventricular ejection fraction, regional wall motion and
myocardial thickness were performed at baseline in eligible
patients who gave consent. Cardiac catheterization was
performed, and PCI of the CTO was attempted according
to routine practice. If the PCI was successful, or unsuccess-
ful but complicated, the procedure was completed, and the
patient was not enrolled. If the PCI was unsuccessful (with
5 min of time spent attempting to cross the CTO with the
guide wire) and uncomplicated, the patient was randomized
to PTMR plus MMT or MMT only. In patients assigned
to PTMR, laser revascularization was performed in the
myocardial territories subtended by the CTO, using the
Eclipse holmium/YAG laser with fluoroscopic guidance, as
previously described (15).
After the procedure, creatine kinase-MB isoenzyme lev-
els were measured every 8 h (3 times/day). Patients were
discharged when clinically stable. After hospital discharge,
the anti-anginal medication was adjusted in all patients to
minimize symptoms and maximize functional status. Clin-
ical follow-up was performed by office visit, interview or
telephone call at 3, 6 and 12 months after discharge. Repeat
exercise testing (using the same modified Bruce protocol as
in the baseline study) was scheduled at 6 and 12 months.
Blinding. Blinding was attempted by use of heavy sedation
and placement of dark goggles over the patient’s eyes during
the entire PCI (with or without PTMR) procedure. More-
over, the seamless transition after randomization from
unsuccessful PCI to either PTMR or conclusion of the
procedure was not revealed to the patient. The physician
investigator was not blinded out of necessity. However, the
randomization assignment was not revealed to the patient,
family or treating physician, was not recorded in the chart
and was not available to the individuals supervising the
follow-up exercise tests. The study blind was not broken
until after the last follow-up period. Finally, to assess the
success of blinding, a questionnaire was completed by the
patient at hospital discharge, designed to elicit the patient’s
perceptions as to treatment assignment (1  PTMR cer-
tain; 2  PTMR probable; 3  randomization uncertain; 4
 MMT [no PTMR] probable; and 5  MMT [no
PTMR] certain).
End points, power analysis and statistics. The trial was
powered to assess the improvement in exercise duration
from baseline to late follow-up in patients undergoing
paired (modified Bruce) exercise tests. In patients unable to
exercise because of refractory angina, the exercise duration
for that test was imputed to 0 s. Assuming that the change
in exercise duration between the baseline and follow-up
exercise test would be 1.5  3.0 min greater in the PTMR
arm than in the MMT arm, the sample size was calculated
to be 64 subjects per group, using a two-tailed analysis with
alpha  0.05 and 80% power. Thus, allowing for dropout
and noncompliance, enrollment of 140 total patients was
planned. Secondary end points included anginal status and
the cumulative occurrence of adverse cardiac events at each
follow-up period.
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CTO  chronic total occlusion
DIRECT  Direct myocardial revascularization In
Regeneration of Endomyocardial Channels
Trial
MI  myocardial infarction
MMT  maximal medical therapy
PCI  percutaneous coronary intervention
PTMR  percutaneous transmyocardial
revascularization
YAG  yttrium aluminum garnet
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Case report forms were prospectively completed by ded-
icated study coordinators, and the data were subsequently
entered into a central computerized database. On-site clin-
ical monitoring was conducted by Eclipse Surgical Tech-
nologies, Inc. (Sunnyvale, California). Exercise tests were
evaluated at an independent electrocardiogram core labora-
tory (Washington University, St. Louis, Missouri).
Categorical variables were compared by the chi-square or
Fisher exact test. Continuous variables are presented as the
mean value  SD or median value (25% to 75% interquar-
tile range) and were compared by the Student t test. All p
values are two-tailed. Cumulative adverse cardiac event rates
were determined by actuarial methods and compared be-
tween the two groups using the log-rank test. All analyses
were performed on an intention-to-treat basis. Significance
was established at p  0.05.
RESULTS
A total of 141 patients at 17 medical centers were random-
ized after failed but uncomplicated PCI of CTO: 71 to
PTMR and 70 to MMT only. The baseline clinical and
angiographic characteristics of the two groups were similar
(Table 1). The patient group was characterized by a high
incidence of diabetes, previous MI, previous CABG and
extensive coronary artery disease (Table 1). The distribution
of failed recanalization of CTO during the procedure was
also similar between the two groups (Fig. 1).
Among patients randomized to PTMR, a total of 20
channels (range 15 to 25 channels) was created in an average
of 1.6 myocardial territories per patient (32% anterior, 62%
inferior, 54% posterolateral and 14% apical). The laser
procedural time was 16 min (range 11 to 30 min).
Clinical outcomes and adverse events. In-hospital com-
plications tended to occur more frequently in patients
assigned to PTMR, as compared with MMT, although
there were no differences in the rates of major adverse
cardiac events at six months (Table 2). Angina was signif-
icantly improved in both groups at six months (Fig. 2).
Angina improved by two or more classes in 56% of patients
who had PTMR and in 38% who received MMT at three
months (p  0.12); at six months, these rates were 49% vs.
37%, respectively (p 0.33). Paired modified Bruce exercise
tests were completed at baseline and at six months in 71
patients (36 treated patients and 35 control subjects; p 
0.97). The exercise duration significantly and similarly
improved from baseline to six months in both groups (86 
38 s after PTMR vs. 69  29 s after MMT [median 64 vs.
52 s]; p 0.73). The numbers of patients in the PTMR and
MMT groups who could not exercise due to refractory
angina were seven and five at baseline and three and three at
six months, respectively.
Efficacy of blinding. Attempts at blinding (through hos-
pital discharge) were reasonably successful in both groups
(Fig. 3). Of patients randomized to PTMR, 44% either





(n  70) p Value
Age, yrs (range) 65 (57–72) 65 (54–71) 0.77
Male gender 82.9% 76.5% 0.35
Diabetes mellitus 41.3% 48.5% 0.40
Hypertension 70.8% 66.1% 0.57
Cigarette smoking 9.7% 16.1% 0.63
Previous MI 64.2% 71.0% 0.41
Previous CABG 84.1% 82.4% 0.79
Anginal class
III 56% 69% 0.11
IV 44% 31%
No. of diseased epicardial
coronary arteries
One 24.6% 29.3%
Two 20.3% 11.8% 0.59
Three 55.1% 58.9%
Diseased vessels
LAD 71.0% 69.1% 0.81
LCx 66.7% 66.2% 0.95
RCA 82.6% 77.9% 0.49
LMCA 17.4% 14.7% 0.67
Left ventricular ejection fraction 52  12% 52  11% 0.89
Data are presented as the percentage of patients, except for age (median value and
range) and left ventricular ejection fraction (mean value  SD).
CABG  coronary artery bypass graft surgery; LAD  left anterior descending
coronary artery; LCx  left circumflex coronary artery; LMCA  left main coronary
artery; MI  myocardial infarction; MMT  maximal medical therapy; PTMR 
percutaneous transmyocardial revascularization; RCA  right coronary artery.
Figure 1. Vessel distribution of chronic total occlusions that were unsuccessfully dilated in patients randomized to percutaneous transmyocardial
revascularization (PTMR) versus maximal medical therapy (MMT). LAD  left anterior descending coronary artery; LCX  left circumflex coronary
artery; RCA  right coronary artery.
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believed that they did not receive PTMR or were not
certain. Of patients randomized to MMT, 75% either
thought they received PTMR or were not certain.
DISCUSSION
This randomized trial demonstrates that in patients with
class III or IV angina due to one or more CTOs that cannot
be percutaneously revascularized, the creation of partial-
thickness myocardial channels with a holmium/YAG laser
does not significantly prolong exercise time or improve
anginal symptoms at intermediate-term follow-up. More-
over, the 82.3% six-month rate of survival free from MI or
revascularization after MMT was not enhanced by PTMR.
Comparison with previous studies. In contrast to the
present study, two previous multicenter, randomized trials
have demonstrated that fluoroscopically guided PTMR may
alleviate angina and prolong the exercise duration in pa-
tients with refractory angina due to end-stage ischemic
heart disease and with no potential for surgical or catheter-
based revascularization—so called “no-option” patients. In
the Potential Angina Class Improvement From Intramyo-
cardial Channels trial, in which 221 no-option patients were
enrolled, the anginal status at six months was improved by
two or more classes in 46% of patients randomized to
PTMR with the Cardiogenesis (Sunnyvale, California)
holmium/YAG laser and in 6% of those treated conserva-
tively (p  0.001), and the exercise duration increased
correspondingly (10). In a randomized trial of 325 no-
option patients, in whom the same Eclipse laser as in the
current study was utilized, patients assigned to PTMR had
an 85-s improvement in exercise time from baseline to six
months, compared with a 58-s decline in control subjects
(p  0.0001); anginal improvement by two or more classes
was present in 55% versus 31% of patients at 12 months,
respectively (p  0.001) (11).
Several patient- and method-related differences between
these previous studies and the present trial may explain the
variance in outcomes. First, the extent of coronary artery
disease and, thus, the degree of ischemia, may have been
greater in the earlier studies. “No-option” patients typically
have diffuse, obliterative coronary atherosclerosis, whereas
patients in the current trial had at least one CTO with a
distal lumen that could visualized and possibly amenable to
PCI or CABG. However, the number of diseased epicardial
vessels and the incidence of previous MI, PCI and CABG
were similar across the three studies, as was the myocardial
density of the laser channels created (10,11).
Blinding and the placebo effect. A notable difference
between the current and previous trials is that in the present
study, extensive efforts were made to blind the patients to
the treatment assignment, by the use of dark goggles and
heavy sedation, and this effort was aided by the performance
of an extended procedure (unsuccessful, uncomplicated
PCI) in all patients before randomization. Blinding of
caregivers was also promoted by restricting access to the
randomization status beyond the catheterization laboratory.
The efficacy of these blinding measures was assessed by a








Death 0% 1.4% 0.49
MI (CK-MB 3 normal) 2.8% 1.4% 0.99
Stroke 0% 0% —
Transient ischemic attack 1.4% 0% 0.99
Ventricular tachycardia or fibrillation 7.0% 0% 0.06
Cardioversion 4.5% 0% 0.12
Pericardial tamponade 4.2% 0% 0.24
Effusions without tamponade 2.8% 0% 0.50
Cumulative 6-month adverse events*
Death 8.6% 8.8% 0.91
MI 4.3% 2.9% 0.68
Any revascularization (PCI or CABG) 4.3% 5.9% 0.65
Death, MI or any revascularization 17.1% 17.7% 0.87
*Kaplan-Meier estimates. Data are presented as the percentage of patients.
CK-MB  creatine kinase-MB isoenzyme; PCI  percutaneous coronary
intervention; other abbreviations as in Table 1.
Figure 2. Canadian Heart Association angina class at six months in the study group. PTMR  percutaneous transmyocardial revascularization; MMT 
maximal medical therapy.
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pre-discharge questionnaire, which verified that most pa-
tients in both groups were uncertain of their treatment
allocation. Indeed, 75% of patients treated conservatively
mistakenly believed they had either received or may have
received the active therapy (PTMR), and as a group, their
exercise tolerance improved by 52 s from baseline to
follow-up. In contrast, conservatively treated no-option
patients in the earlier Eclipse study had a marked decline in
their exercise time during follow-up (11), perhaps a conse-
quence of less successful blinding and the patient’s resigna-
tion to continued symptoms (Fig. 4). Importantly, these
data are concordant with the findings of Direct myocardial
revascularization In Regeneration of Endomyocardial
Channels Trial (DIRECT), a recently reported random-
ized, blinded study of PTMR in 298 no-option patients
treated with the Johnson & Johnson (Warren, New Jersey)
holmium/YAG laser with electromechanical map guidance,
in whom no incremental improvement in angina or exercise
capacity was found after PTMR (14). The DIRECT data
are particularly relevant, as anginal status and exercise
duration had improved in a previous unblinded registry
using this system (16). Thus, these studies reinforce the
power of the placebo effect, as well as the importance of
adequate blinding whenever possible (12,13).
Finally, the results of a fourth, smaller, randomized trial,
the Blinded Evaluation of Laser Intervention Electively for
Angina Pectoris study, in which PTMR with the Eclipse
holmium/YAG laser was compared with a truly blinded
sham procedure in 82 no-option patients, were recently
reported (17). Compared with the sham control group,
PTMR resulted in a greater relief of angina at six months
(2 class improvement in 41% vs. 13%, p  0.004).
However, the total exercise duration from baseline to six
months increased by just 10 s in the PTMR arm and 7 s in
the sham arm (p  NS), suggesting that the laser’s photo-
Figure 3. Results of the pre-discharge questionnaire of treatment assignment. PTMR percutaneous transmyocardial revascularization; MMTmaximal
medical therapy.
Figure 4. Improvement in exercise duration from baseline to six months in
patients randomized to percutaneous transmyocardial revascularization
(white bars) with the Eclipse holmium/yttrium aluminum garnet laser
versus maximal medical therapy (black bars) in the present study (patients
with non-revascularizable chronic total occlusions (CTOs); left bars)
compared with a previous study with the same device in a different patient
group (patients with end-stage ischemic heart disease with no revascular-
ization options; right bars).
1585JACC Vol. 39, No. 10, 2002 Stone et al.
May 15, 2002:1581–7 Percutaneous Transmyocardial Laser Revascularization
acoustic effect may reduce some patient’s pain perception,
without relieving ischemia (18,19).
Study limitations. The principal limitation of the study is
that only 71 of 141 randomized patients had paired baseline
and follow-up exercise tests, rather than 128, for which the
sample size of 140 was chosen. However, the principal end
point—the difference in improvement in exercise time from
baseline to six months between the two groups—was
powered to 90 s; given the observed mean difference of only
17 s in 71 patients, the average increment in exercise
duration improvement would have had to be 181 s in 57
additional patients for the study to be statistically positive, a
magnitude of improvement which has not yet been seen in
any PTMR investigation. Also, data from the 12-month
planned functional tests and clinical status are not currently
available, although the trend toward a reduction in angina
seen at three months was less apparent at six months,
making it doubtful that longer follow-up would have been
revealing. Nonetheless, a small benefit of PTMR in improv-
ing exercise capacity or relieving angina in patients with a
nonrecanalizable CTO cannot be excluded, and may have
been revealed by a larger sample size and more extended
follow-up. However, the trend observed in the present
study—that is, greater procedural complications in patients
undergoing PTMR—may also have become significant in a
larger trial. As collateral vessels were not quantified, the
impact of angiographically visible collateral blood flow to
the myocardial target zones on the outcome of PTMR is
unknown. Finally, myocardial perfusion or metabolic imag-
ing was not performed, although most previous studies have
not demonstrated improved perfusion with PTMR (20,21).
Clinical implications. Based on this study, PTMR should
not be considered for patients with class III or IV angina
caused solely by a nonrecanalizable CTO. However, given
the conflicting results in the aforementioned randomized
trials, which included different patient groups, different
degrees of blinding and different holmium/YAG systems,
one final, large-scale, blinded, randomized trial (preferably
with the Cardiogenesis/Eclipse laser system, in which pos-
itive results in no-option patients have been reported) would
be essential to definitively exclude (or potentially establish)
a role for PTMR in patients who are otherwise poor
candidates for traditional revascularization modalities.
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